Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TOWA Pharmaceutical CoTWAPF 69 EV-to-OCF is 11.60 as of Aug. 15, 2026, which is 7% below its 10-year median of 12.44. GuruFocus rates TWAPF with a GF Score™ of 69/100 and a GF Value™ of $14.20 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,006 Drug Manufacturers companies, TOWA Pharmaceutical Co ranks worse than 53.88% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, TOWA Pharmaceutical Co's Enterprise Value is $2,310 Mil.
TOWA Pharmaceutical Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $199 Mil. Therefore, TOWA Pharmaceutical Co's EV-to-OCF for today is 11.60.
The historical rank and industry rank for TOWA Pharmaceutical Co's EV-to-OCF or its related term are showing as below:
TWAPF'
s EV-to-OCF Range Over the Past 10 Years
Min: -55.83 Med: 12.44 Max: 63.1
Current: 12.35
During the past 13 years, the highest EV-to-OCF of TOWA Pharmaceutical Co was 63.10. The lowest was -55.83. And the median was 12.44.
TWAPF's EV-to-OCF is ranked worse than 53.88% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 11.045
vs TWAPF: 12.35
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
TOWA Pharmaceutical Co (OTCPK:TWAPF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
TOWA Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
TOWA Pharmaceutical Co's share price for today is $25.98.
TOWA Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.776.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, TOWA Pharmaceutical Co's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TOWA Pharmaceutical Co EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TOWA Pharmaceutical Co's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where TOWA Pharmaceutical Co's EV-to-OCF falls into.
TOWA Pharmaceutical Co's current Enterprise Value is $2,310 Mil.
TOWA Pharmaceutical Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $199 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TOWA Pharmaceutical Co (TWAPF) has a EV-to-OCF of 11.60 as of Aug. 15, 2026. This is near median its historical median of 12.44. According to the industry distribution chart, TOWA Pharmaceutical Co ranks #542 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 53.9%.
Is TOWA Pharmaceutical Co's EV-to-OCF too high?
TOWA Pharmaceutical Co's current EV-to-OCF of 11.60 is near median its 10-year median of 12.44. The Drug Manufacturers industry median EV-to-OCF is 11.05. TOWA Pharmaceutical Co's value of 11.60 is 5% above this industry median. Based on the distribution chart, TOWA Pharmaceutical Co ranks #542 out of 1006 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, TOWA Pharmaceutical Co has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TOWA Pharmaceutical Co's EV-to-OCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, TOWA Pharmaceutical Co ranks #542 out of 1006 companies for EV-to-OCF. This places TOWA Pharmaceutical Co in the lower half of its industry. The industry median EV-to-OCF is 11.05. TOWA Pharmaceutical Co's value of 11.60 is 5% above this benchmark. While the company's 10-year median is 12.44 vs. the industry median of 11.05, TOWA Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.05, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TOWA Pharmaceutical Co's current EV-to-OCF of 11.60 is 5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TOWA Pharmaceutical Co's current EV-to-OCF is 11.60, which is near median its own 10-year median of 12.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TOWA Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, TOWA Pharmaceutical Co (TWAPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $14.20, compared to a current price of $25.98 — trading 83% above its estimated fair value. The current EV-to-OCF is 11.60, which is near median its 10-year median of 12.44 and 5% above the Drug Manufacturers industry median of 11.05. TOWA Pharmaceutical Co's overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For TOWA Pharmaceutical Co (TWAPF), the current EV-to-OCF is 11.60 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TOWA Pharmaceutical Co (TWAPF) Overvalued in 2026?
Based on GuruFocus' analysis, TOWA Pharmaceutical Co stock appears to be overvalued.
The current stock price of $25.98 is trading 83% above its estimated GF Value™ of $14.20.
GuruFocus considers TOWA Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for TWAPF:
EV-to-OCF: 11.60 (near median its 10-year median of 12.44)
GF Value™: $14.20 vs. price of $25.98 (83% above fair value)
Industry Position: 5% above the Drug Manufacturers median (#542 of 1006)
No single metric tells the full story. See the TWAPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TOWA Pharmaceutical Co Ltd is a Japan based pharmaceutical company engaged in research and development, production, and marketing of generic drugs. It also provides drug consulting services for patients and their families and relatives. It organizes academic seminars for medical professionals and posts articles in journals. It participates in training for pharmacists. The company has three main plants in operation namely Osaka plant, Okayama plant, and Yamagata plant. Towa has offers more than 500 drugs to meet the diverse therapeutic requirements including lifestyle related diseases such as hypertension and diabetes, digestive system diseases, nervous system diseases and allergic diseases, vitamins and antibiotics.
69GF Score
Get the complete analysis for TWAPF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TWAPF has been successfully added to your 
